Movement Alert｜Abbott Laboratories Rises 3.21% in Regular Trading, FDA Approval of Colorectal Cancer Blood Screening Test Continues to Boost Shares

Market Focus08-03 21:57

On August 3, Abbott Laboratories rose 3.21% in regular trading, trading at $108.07/share, with turnover of $95.64 million. The stock continued to gain momentum following the FDA's recent approval of SimpleScreen CRC, a blood-based colorectal cancer screening test co-developed with Freenome.

The FDA formally approved the SimpleScreen CRC test, which targets adults aged 45 and older at average risk for colorectal cancer. Under the commercial agreement between the two companies, Abbott will exclusively commercialize the test in the United States beginning this fall. As part of the arrangement, Abbott will pay Freenome a $100 million milestone payment tied to the FDA approval. The non-invasive screening test represents a significant advancement in colorectal cancer detection and deepens the strategic collaboration between the two companies in the precision medicine market.

Within the Health Care Equipment sector where Abbott Laboratories belongs, the overall sector showed broad strength. Among individual stocks, Intuitive Surgical up 6.04%, Boston Scientific up 4.45%, DexCom up 4.03%, Integer up 2.73%, Stryker up 2.34%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122581709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122581709","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abbott Laboratories Rises 3.21% in Regular Trading, FDA Approval of Colorectal Cancer Blood Screening Test Continues to Boost Shares","media":"Market Focus","content":"<p><p>On August 3, Abbott Laboratories rose 3.21% in regular trading, trading at $108.07/share, with turnover of $95.64 million. The stock continued to gain momentum following the FDA's recent approval of SimpleScreen CRC, a blood-based colorectal cancer screening test co-developed with Freenome.</p><p>The FDA formally approved the SimpleScreen CRC test, which targets adults aged 45 and older at average risk for colorectal cancer. Under the commercial agreement between the two companies, Abbott will exclusively commercialize the test in the United States beginning this fall. As part of the arrangement, Abbott will pay Freenome a $100 million milestone payment tied to the FDA approval. The non-invasive screening test represents a significant advancement in colorectal cancer detection and deepens the strategic collaboration between the two companies in the precision medicine market.</p><p>Within the Health Care Equipment sector where Abbott Laboratories belongs, the overall sector showed broad strength. Among individual stocks, Intuitive Surgical up 6.04%, Boston Scientific up 4.45%, DexCom up 4.03%, Integer up 2.73%, Stryker up 2.34%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abbott Laboratories Rises 3.21% in Regular Trading, FDA Approval of Colorectal Cancer Blood Screening Test Continues to Boost Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abbott Laboratories Rises 3.21% in Regular Trading, FDA Approval of Colorectal Cancer Blood Screening Test Continues to Boost Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, Abbott Laboratories rose 3.21% in regular trading, trading at $108.07/share, with turnover of $95.64 million. The stock continued to gain momentum following the FDA's recent approval of SimpleScreen CRC, a blood-based colorectal cancer screening test co-developed with Freenome.</p><p>The FDA formally approved the SimpleScreen CRC test, which targets adults aged 45 and older at average risk for colorectal cancer. Under the commercial agreement between the two companies, Abbott will exclusively commercialize the test in the United States beginning this fall. As part of the arrangement, Abbott will pay Freenome a $100 million milestone payment tied to the FDA approval. The non-invasive screening test represents a significant advancement in colorectal cancer detection and deepens the strategic collaboration between the two companies in the precision medicine market.</p><p>Within the Health Care Equipment sector where Abbott Laboratories belongs, the overall sector showed broad strength. Among individual stocks, Intuitive Surgical up 6.04%, Boston Scientific up 4.45%, DexCom up 4.03%, Integer up 2.73%, Stryker up 2.34%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1122581709","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122581709","pubTimestamp":1785765472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, Abbott Laboratories rose 3.21% in regular trading, trading at $108.07/share, with turnover of $95.64 million. The stock continued to gain momentum following the FDA's recent approval of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"动向提醒|雅培制药常规交易上涨3.21%，FDA批准结直肠癌血液筛查测试继续提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"On August 3, Abbott Laboratories rose 3.21% in regular trading, trading at $108.07/share, with turnover of $95.64 million. The stock continued to gain momentum following the FDA's recent approval of SimpleScreen CRC, a blood-based colorectal cancer screening test co-developed with Freenome.The FDA formally approved the SimpleScreen CRC test, which targets adults aged 45 and older at average risk for colorectal cancer. Under the commercial agreement between the two companies, Abbott will exclusively commercialize the test in the United States beginning this fall. As part of the arrangement, Abbott will pay Freenome a $100 million milestone payment tied to the FDA approval. The non-invasive screening test represents a significant advancement in colorectal cancer detection and deepens the strategic collaboration between the two companies in the precision medicine market.Within the Health Care Equipment sector where Abbott Laboratories belongs, the overall sector showed broad strength. Among individual stocks, Intuitive Surgical up 6.04%, Boston Scientific up 4.45%, DexCom up 4.03%, Integer up 2.73%, Stryker up 2.34%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122581709","isCrawlerRequest":true}